UK prescription product trends: annual review 2017

Introducing MIMS' annual review of developments in the UK prescription product market.

As the first point of call for companies needing to communicate their product updates to prescribers, MIMS is uniquely placed to observe trends in the pharmaceutical marketplace.
As the first point of call for companies needing to communicate their product updates to prescribers, MIMS is uniquely placed to observe trends in the pharmaceutical marketplace.

In this report available exclusively to MIMS corporate subscribers, we review the branded products added to MIMS in 2017, analysing them by classification, route of administration, company, therapeutic area, indication, molecule type, pharmacological class, active ingredients and novelty. As a reference point, we compare the findings with data from 2016.

We highlight the new small molecules and biologics that were added to MIMS in 2017, including several entirely new pharmacological classes.

In addition, we review the products that were removed from MIMS in 2017 and outline some new products expected to launch in 2018.

MIMS corporate subscribers can access the report using the password provided by email.

View UK prescription product trends report
(password required)

To take out a multi-user or domain licence to MIMS and receive the product trends report in full, please contact us.

A MIMS corporate subscription offers:

  • Online access to drug information on over 3000 products
  • Latest drug information – updated daily
  • News on changes that affect prescribing
  • Exclusive MIMS drug reference tables for quick look-up, including HRT preparations and antidepressant switching advice
  • At-a-glance summaries of national treatment guidelines
  • Online visual guides to help you identify, compare and recommend suitable devices
  • MIMS Clinics: online prescribing resource centres for key therapy areas
  • Quarterly print issue (available upon request)
  • Annual report on GP prescribing behaviour with an opportunity to submit your own research questions (subject to editorial approval)
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...

New MIMS table helps prescribers choose asthma inhalers

New MIMS table helps prescribers choose asthma inhalers

Prescribers can now turn to a handy MIMS comparison...

LABA/Corticosteroid Combination Inhalers for the Treatment of Asthma

LABA/Corticosteroid Combination Inhalers for the Treatment of Asthma

Key information on asthma combination inhalers.

MIMS Learning's top 25 learning modules in 2018: which topics were the hottest?

MIMS Learning's top 25 learning modules in 2018: which topics were the hottest?

Discover the hottest topics in primary care learning,...